Retirement Planning Co of New England Inc. Purchases 858 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Retirement Planning Co of New England Inc. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,342 shares of the biopharmaceutical company’s stock after purchasing an additional 858 shares during the quarter. Retirement Planning Co of New England Inc.’s holdings in Gilead Sciences were worth $847,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Oppenheimer Asset Management Inc. grew its position in Gilead Sciences by 20.5% during the second quarter. Oppenheimer Asset Management Inc. now owns 183,224 shares of the biopharmaceutical company’s stock worth $12,571,000 after buying an additional 31,148 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Gilead Sciences by 27.0% in the second quarter. Parallel Advisors LLC now owns 58,123 shares of the biopharmaceutical company’s stock worth $3,988,000 after purchasing an additional 12,349 shares during the last quarter. Dai ichi Life Insurance Company Ltd lifted its position in Gilead Sciences by 42.5% during the second quarter. Dai ichi Life Insurance Company Ltd now owns 377,017 shares of the biopharmaceutical company’s stock valued at $25,867,000 after purchasing an additional 112,395 shares during the last quarter. HBK Sorce Advisory LLC grew its stake in Gilead Sciences by 17.8% in the 2nd quarter. HBK Sorce Advisory LLC now owns 43,445 shares of the biopharmaceutical company’s stock worth $2,981,000 after buying an additional 6,556 shares in the last quarter. Finally, Zions Bancorporation N.A. increased its holdings in shares of Gilead Sciences by 15.7% in the 2nd quarter. Zions Bancorporation N.A. now owns 108,280 shares of the biopharmaceutical company’s stock worth $7,429,000 after buying an additional 14,714 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the sale, the insider now directly owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The disclosure for this sale can be found here. Insiders have sold 36,847 shares of company stock worth $3,002,940 over the last 90 days. 0.16% of the stock is owned by company insiders.

Gilead Sciences Trading Up 0.5 %

GILD opened at $82.81 on Friday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The business has a 50 day simple moving average of $75.48 and a two-hundred day simple moving average of $70.86. The firm has a market capitalization of $103.10 billion, a price-to-earnings ratio of 230.03, a PEG ratio of 2.80 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. The company had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. Analysts predict that Gilead Sciences, Inc. will post 3.78 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.72%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences’s payout ratio is 855.56%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Truist Financial lifted their price objective on shares of Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. BMO Capital Markets raised their price objective on Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $95.00 target price on shares of Gilead Sciences in a research note on Wednesday. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $70.00 price target on shares of Gilead Sciences in a research note on Monday, September 9th. Twelve analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $82.06.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.